Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination Therapy with Monoamine Oxidase Inhibitors and Other Antidepressants or Stimulants: Strategies for the Management of Treatment‐Resistant Depression
Samantha J. Thomas, Mi-Rae Shin, Melvin G. McInnis, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2015) Vol. 35, Iss. 4, pp. 433-449
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities
Stephen V. Faraone
Neuroscience & Biobehavioral Reviews (2018) Vol. 87, pp. 255-270
Open Access | Times Cited: 511
Tranylcypromine in mind (Part I): Review of pharmacology
S. Ulrich, Roland Ricken, Mazda Adli
European Neuropsychopharmacology (2017) Vol. 27, Iss. 8, pp. 697-713
Open Access | Times Cited: 224
Neurobiology of depression in Parkinson’s disease: Insights into epidemiology, molecular mechanisms and treatment strategies
Mir Hilal Ahmad, M. Moshahid A. Rizvi, Mansoor Ali, et al.
Ageing Research Reviews (2023) Vol. 85, pp. 101840-101840
Closed Access | Times Cited: 59
Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes
Natalia de M. Lyra e Silva, Minh P. Lam, Cláudio N. Soares, et al.
Frontiers in Psychiatry (2019) Vol. 10
Open Access | Times Cited: 129
Gut microbiome: A potential indicator for predicting treatment outcomes in major depressive disorder
Zaiquan Dong, Xiaoling Shen, Yanni Hao, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 46
Pathogenesis and treatment of depression: Role of diet in prevention and therapy
Weronika Mrozek, Justyna Socha, Klara Sidorowicz, et al.
Nutrition (2023) Vol. 115, pp. 112143-112143
Open Access | Times Cited: 40
The brain-gut-microbiota interplay in depression: A key to design innovative therapeutic approaches
Angelica Varesi, Lucrezia Irene Maria Campagnoli, Salvatore Chirumbolo, et al.
Pharmacological Research (2023) Vol. 192, pp. 106799-106799
Open Access | Times Cited: 39
Type-B monoamine oxidase inhibitors in neurological diseases
Marika Alborghetti, Edoardo Bianchini, Lanfranco De Carolis, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 1, pp. 16-21
Open Access | Times Cited: 28
Involvement of D1 and D2 dopamine receptors in the antidepressant-like effects of selegiline in maternal separation model of mouse
Shayan Amiri, Hossein Amini-Khoei, Ali Mohammadi-Asl, et al.
Physiology & Behavior (2016) Vol. 163, pp. 107-114
Closed Access | Times Cited: 63
A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?
Seetal Dodd, Michael Bauer, André F. Carvalho, et al.
The World Journal of Biological Psychiatry (2020) Vol. 22, Iss. 7, pp. 483-494
Closed Access | Times Cited: 55
Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review
Alice Caldiroli, Enrico Capuzzi, Ilaria Tagliabue, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 13070-13070
Open Access | Times Cited: 43
Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
Amber N. Edinoff, Connor R. Swinford, Amira S. Odisho, et al.
Health psychology research (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 36
Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively
Samuel R. Chamberlain, David S. Baldwin
CNS Drugs (2021) Vol. 35, Iss. 7, pp. 703-716
Open Access | Times Cited: 36
Anti-depressant-like effect of fermented Gastrodia elata Bl. by regulating monoamine levels and BDNF/NMDAR pathways in mice
Ming Gao, Yi Wu, Lishou Yang, et al.
Journal of Ethnopharmacology (2022) Vol. 301, pp. 115832-115832
Closed Access | Times Cited: 24
Interactions Between Antidepressants and Intestinal Microbiota
Feiyu Xu, Qinglian Xie, Weihong Kuang, et al.
Neurotherapeutics (2023) Vol. 20, Iss. 2, pp. 359-371
Closed Access | Times Cited: 13
Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study
Sofia Pappa, Moulesh Shah, Sophie Young, et al.
BJPsych Open (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Michael Entzeroth, Anil K. Ratty
Open Journal of Depression (2017) Vol. 06, Iss. 02, pp. 31-68
Open Access | Times Cited: 40
Mitochondria targeting fluorescent probe for MAO-A and the application in the development of drug candidate for neuroinflammation
Jia‐Rong Wu, Chaoyan Han, Xudong Cao, et al.
Analytica Chimica Acta (2022) Vol. 1199, pp. 339573-339573
Closed Access | Times Cited: 22
Hydroxynorketamine, but not ketamine, acts via α7 nicotinic acetylcholine receptor to control presynaptic function and gene expression
Debarpan Guhathakurta, Aneta Petrušková, Enes Yağız Akdaş, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Elevating the level of hypoxia inducible factor may be a new potential target for the treatment of depression
Ilhyang Kang, Douglas G. Kondo, Jungyoon Kim, et al.
Medical Hypotheses (2020) Vol. 146, pp. 110398-110398
Closed Access | Times Cited: 28
Anxiolytic-like and antidepressant-like effects of ethanol extract of Terminalia chebula in mice
Vasudevan Mani, Sultan Sajid, Syed Imam Rabbani, et al.
Journal of Traditional and Complementary Medicine (2021) Vol. 11, Iss. 6, pp. 493-502
Open Access | Times Cited: 26
The Contribution of Genetic Testing in Optimizing Therapy for Patients with Recurrent Depressive Disorder
Rita Ioana Platona, Florica Voiţă-Mekereş, Cristina Tudoran, et al.
Clinics and Practice (2024) Vol. 14, Iss. 3, pp. 703-717
Open Access | Times Cited: 3
Curcumin-based pyrazoline analogues as selective inhibitors of human monoamine oxidase A
Chandrani Nath, Vishnu Nayak Badavath, Abhishek Thakur, et al.
MedChemComm (2018) Vol. 9, Iss. 7, pp. 1164-1171
Open Access | Times Cited: 30
Combination of electroconvulsive stimulation with ketamine or escitalopram protects the brain against inflammation and oxidative stress induced by maternal deprivation and is critical for associated behaviors in male and female rats
Helena M. Abelaira, Thayse Rosa, Airam B. de Moura, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 3, pp. 1452-1475
Closed Access | Times Cited: 15
Mushroom Natural Products in Neurodegenerative Disease Drug Discovery
Arjuna Abitbol, Brody Mallard, Evelin Tiralongo, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3938-3938
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top